Annamycin Phase III AML trial reports triple remission rate
The Phase III AML trial for an annamycin-based therapy reported remission rates three times higher than control, with no cardiotoxicity reported.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.